Skip to main content
Top
Published in:

Open Access 09-12-2024 | Diabetes | REVIEW

Mind in Metabolism – A Comprehensive Literature Review on Diabetes and its Connections to Obsessive Compulsive Disorder, Schizophrenia, and Bipolar Disorder

Authors: Anja Cannon, Caitlon Jacoby, Allyson S. Hughes

Published in: Current Diabetes Reports | Issue 1/2025

Login to get access

Abstract

Purpose of Review

The co-occurrence of diabetes and mental illnesses such as bipolar disorder (BD), obsessive-compulsive disorder (OCD), and schizophrenia creates significant barriers for both people with diabetes (PWD) and their healthcare teams. This literature review provides an analysis of the relationship between diabetes and mental illnesses through exploring epidemiology, shared risk factors, and clinical implications. The aim is to enhance the understanding of these complex comorbidities to guide and improve future research and clinical practice.

Recent Findings

Recent research suggests a strong link between mental illness, metabolic syndrome, and diabetes. Studies show that BD has a robust relationship with metabolic disease and the antipsychotic medications used in treatment for many mental illnesses are strongly associated with weight gain and metabolic disease. However, there is limited research exploring the bidirectional relationship that diabetes has with BD, schizophrenia, and OCD.

Summary

While research exists on the link between diabetes and mental conditions such as depression and anxiety, little research has examined schizophrenia, OCD and BD. The findings noted in this review suggest gaps in treatment options, healthcare services, and social support. While this paper provides a foundation for future progress, advancement in this field will require a collaborative effort from researchers, healthcare professionals, and community outreach programs to effectively close the gaps in care noted in these patient populations.
Literature
1.
go back to reference Sun H, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice; 2021. Sun H, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice; 2021.
2.
go back to reference Lin J, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metrics. 2018;16(1):9.CrossRef Lin J, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metrics. 2018;16(1):9.CrossRef
3.
go back to reference Owens-Gary MD, et al. The importance of addressing Depression and Diabetes distress in adults with type 2 diabetes. J Gen Intern Med. 2019;34(2):320–4.PubMedCrossRef Owens-Gary MD, et al. The importance of addressing Depression and Diabetes distress in adults with type 2 diabetes. J Gen Intern Med. 2019;34(2):320–4.PubMedCrossRef
4.
go back to reference Zhang P, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301.PubMedCrossRef Zhang P, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301.PubMedCrossRef
5.
go back to reference Lawrence D, Jablensky HC. AV, Preventable physical illness in people with Mental Illness. Perth: The University of Western Australia; 2001. Lawrence D, Jablensky HC. AV, Preventable physical illness in people with Mental Illness. Perth: The University of Western Australia; 2001.
7.
go back to reference Flury R, Solomons L. Too often missing: making emotional and psychological support routine in diabetes care. Editor: D. UK; 2019. May 14 2019. Flury R, Solomons L. Too often missing: making emotional and psychological support routine in diabetes care. Editor: D. UK; 2019. May 14 2019.
8.
go back to reference Polonsky WH, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–31.PubMedCrossRef Polonsky WH, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–31.PubMedCrossRef
9.
go back to reference Fisher L, Polonsky WH, Hessler D. Addressing diabetes distress in clinical care: a practical guide. Diabet Med. 2019;36(7):803–12.PubMedCrossRef Fisher L, Polonsky WH, Hessler D. Addressing diabetes distress in clinical care: a practical guide. Diabet Med. 2019;36(7):803–12.PubMedCrossRef
10.
go back to reference Skinner TC, Joensen L, Parkin T. Twenty-five years of diabetes distress research. Diabet Med. 2020;37(3):393–400.PubMedCrossRef Skinner TC, Joensen L, Parkin T. Twenty-five years of diabetes distress research. Diabet Med. 2020;37(3):393–400.PubMedCrossRef
11.
go back to reference Ee C, et al. An integrative collaborative care model for people with mental illness and physical comorbidities. Int J Mental Health Syst. 2020;14(1):83.CrossRef Ee C, et al. An integrative collaborative care model for people with mental illness and physical comorbidities. Int J Mental Health Syst. 2020;14(1):83.CrossRef
12.
13.
go back to reference ElSayed NA et al. Addendum. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S19-S40. Diabetes Care, 2023. 46(9): p. 1715. ElSayed NA et al. Addendum. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S19-S40. Diabetes Care, 2023. 46(9): p. 1715.
14.
go back to reference Vancampfort D, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265–74.PubMedCrossRef Vancampfort D, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265–74.PubMedCrossRef
16.
go back to reference Katon J. Epidemiology and treatment of depression in patients with chronic medical illness. Dialog Clin Neurosci. 2011;13(1):7–23.CrossRef Katon J. Epidemiology and treatment of depression in patients with chronic medical illness. Dialog Clin Neurosci. 2011;13(1):7–23.CrossRef
17.
go back to reference Kemp CG, et al. Effect of a collaborative care model on anxiety symptoms among patients with depression and diabetes in India: the INDEPENDENT randomized clinical trial. Gen Hosp Psychiatry. 2022;74:39–45.PubMedCrossRef Kemp CG, et al. Effect of a collaborative care model on anxiety symptoms among patients with depression and diabetes in India: the INDEPENDENT randomized clinical trial. Gen Hosp Psychiatry. 2022;74:39–45.PubMedCrossRef
18.
go back to reference Huang Y, et al. Collaborative care for patients with depression and diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry. 2013;13(1):260.PubMedPubMedCentralCrossRef Huang Y, et al. Collaborative care for patients with depression and diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry. 2013;13(1):260.PubMedPubMedCentralCrossRef
19.
go back to reference Lieberman JA. 3rd, Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry, 2004. 6(Suppl 2): pp. 8–13. Lieberman JA. 3rd, Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry, 2004. 6(Suppl 2): pp. 8–13.
20.
go back to reference Chokhawala K, Stevens L. Antipsychotic Medications, in StatPearls. 2024, StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.: Treasure Island (FL). Chokhawala K, Stevens L. Antipsychotic Medications, in StatPearls. 2024, StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.: Treasure Island (FL).
21.
22.
go back to reference Siegel-Ramsay JE, et al. Experiences that matter in bipolar disorder: a qualitative study using the capability, comfort and calm framework. Int J Bipolar Disorders. 2023;11(1):13.CrossRef Siegel-Ramsay JE, et al. Experiences that matter in bipolar disorder: a qualitative study using the capability, comfort and calm framework. Int J Bipolar Disorders. 2023;11(1):13.CrossRef
23.
go back to reference Merikangas KR, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241–51.PubMedPubMedCentralCrossRef Merikangas KR, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241–51.PubMedPubMedCentralCrossRef
24.
go back to reference McLntyre RS, et al. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialog Clin Neurosci. 2008;10(2):203–13.CrossRef McLntyre RS, et al. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialog Clin Neurosci. 2008;10(2):203–13.CrossRef
25.
go back to reference Hossain S, et al. Medical and Psychiatric comorbidities in bipolar disorder: insights from National Inpatient Population-based study. Cureus. 2019;11(9):e5636.PubMedPubMedCentral Hossain S, et al. Medical and Psychiatric comorbidities in bipolar disorder: insights from National Inpatient Population-based study. Cureus. 2019;11(9):e5636.PubMedPubMedCentral
26.
27.
go back to reference Alanazi A et al. Prevalence and Correlation of Metabolic Syndrome in Patients with Bipolar Disorder in NGHA, Riyadh. BioMed research international, 2022. 2022: p. 5847175. Alanazi A et al. Prevalence and Correlation of Metabolic Syndrome in Patients with Bipolar Disorder in NGHA, Riyadh. BioMed research international, 2022. 2022: p. 5847175.
28.
go back to reference Dodd S, et al. The role of metformin as a treatment for neuropsychiatric illness. Eur Neuropsychopharmacol. 2022;64:32–43.PubMedCrossRef Dodd S, et al. The role of metformin as a treatment for neuropsychiatric illness. Eur Neuropsychopharmacol. 2022;64:32–43.PubMedCrossRef
29.
go back to reference Pahwa M, et al. Cardiometabolic and endocrine comorbidities in women with bipolar disorder: a systematic review. J Affect Disord. 2023;323:841–59.PubMedCrossRef Pahwa M, et al. Cardiometabolic and endocrine comorbidities in women with bipolar disorder: a systematic review. J Affect Disord. 2023;323:841–59.PubMedCrossRef
31.
go back to reference Kittel-Schneider S et al. Prevalence of prediabetes and diabetes mellitus type II in bipolar disorder. Front Psychiatry, 2020. 11. Kittel-Schneider S et al. Prevalence of prediabetes and diabetes mellitus type II in bipolar disorder. Front Psychiatry, 2020. 11.
32.
go back to reference Liu YK, et al. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2022;300:449–61.PubMedCrossRef Liu YK, et al. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2022;300:449–61.PubMedCrossRef
33.
go back to reference Chien IC, et al. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry. 2010;32(6):577–82.PubMedCrossRef Chien IC, et al. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry. 2010;32(6):577–82.PubMedCrossRef
34.
go back to reference Crump C, et al. Comorbidities and mortality in bipolar disorder: a Swedish National Cohort Study. JAMA Psychiatry. 2013;70(9):931–9.PubMedCrossRef Crump C, et al. Comorbidities and mortality in bipolar disorder: a Swedish National Cohort Study. JAMA Psychiatry. 2013;70(9):931–9.PubMedCrossRef
35.
go back to reference Tsai C-L, et al. Risk of hyperglycemic crisis episode in diabetic patients with bipolar disorder: a nationwide population-based cohort study. J Affect Disord. 2019;257:281–6.PubMedCrossRef Tsai C-L, et al. Risk of hyperglycemic crisis episode in diabetic patients with bipolar disorder: a nationwide population-based cohort study. J Affect Disord. 2019;257:281–6.PubMedCrossRef
36.
go back to reference Rohde C, et al. Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: a nationwide study of 30,451 patients. Bipolar Disord. 2023;25(4):323–34.PubMedCrossRef Rohde C, et al. Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: a nationwide study of 30,451 patients. Bipolar Disord. 2023;25(4):323–34.PubMedCrossRef
37.
go back to reference Scheuer SH, et al. Trends in incidence of hospitalization for Hypoglycemia and Diabetic Ketoacidosis in individuals with type 1 or type 2 diabetes with and without severe Mental illness in Denmark from 1996 to 2020: a Nationwide Study. Diabetes Care. 2024;47(6):1065–73.PubMedCrossRef Scheuer SH, et al. Trends in incidence of hospitalization for Hypoglycemia and Diabetic Ketoacidosis in individuals with type 1 or type 2 diabetes with and without severe Mental illness in Denmark from 1996 to 2020: a Nationwide Study. Diabetes Care. 2024;47(6):1065–73.PubMedCrossRef
38.
go back to reference Chu C-W, Liang C-S. Mood state as a blood glucose modulator in a patient with bipolar disorder and diabetes mellitus: a case report. Australian New Z J Psychiatry. 2018;52(10):1004–5.CrossRef Chu C-W, Liang C-S. Mood state as a blood glucose modulator in a patient with bipolar disorder and diabetes mellitus: a case report. Australian New Z J Psychiatry. 2018;52(10):1004–5.CrossRef
39.
go back to reference Muijs LT, et al. Glucose variability and mood in adults with diabetes: a systematic review. Endocrinol Diabetes Metab. 2021;4(1):e00152.PubMedCrossRef Muijs LT, et al. Glucose variability and mood in adults with diabetes: a systematic review. Endocrinol Diabetes Metab. 2021;4(1):e00152.PubMedCrossRef
40.
go back to reference Association AP. Diagnostic and statistical manual of Mental disorders. 5 ed. American Psychiatric Association; 2013. Association AP. Diagnostic and statistical manual of Mental disorders. 5 ed. American Psychiatric Association; 2013.
42.
go back to reference Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic Schizophrenia. N Engl J Med. 2005;353(12):1209–23.PubMedCrossRef Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic Schizophrenia. N Engl J Med. 2005;353(12):1209–23.PubMedCrossRef
43.
go back to reference Smith M, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406–11.PubMedCrossRef Smith M, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406–11.PubMedCrossRef
44.
go back to reference Werner S, Malaspina D, Rabinowitz J. Socioeconomic status at birth is associated with risk of schizophrenia: population-based multilevel study. Schizophr Bull. 2007;33(6):1373–8.PubMedPubMedCentralCrossRef Werner S, Malaspina D, Rabinowitz J. Socioeconomic status at birth is associated with risk of schizophrenia: population-based multilevel study. Schizophr Bull. 2007;33(6):1373–8.PubMedPubMedCentralCrossRef
45.
go back to reference O’Neill EA. The role of diabetes in Predicting Employment Status for individuals with bipolar disorder. Social work Public Health. 2016;31(7):646–55.CrossRef O’Neill EA. The role of diabetes in Predicting Employment Status for individuals with bipolar disorder. Social work Public Health. 2016;31(7):646–55.CrossRef
46.
go back to reference Kurdyak P, et al. Diabetes quality of care and outcomes: comparison of individuals with and without schizophrenia. Gen Hosp Psychiatry. 2017;46:7–13.PubMedCrossRef Kurdyak P, et al. Diabetes quality of care and outcomes: comparison of individuals with and without schizophrenia. Gen Hosp Psychiatry. 2017;46:7–13.PubMedCrossRef
48.
go back to reference Le TKC et al. Insulin signaling and its application. Front Endocrinol, 2023. 14. Le TKC et al. Insulin signaling and its application. Front Endocrinol, 2023. 14.
49.
go back to reference Grassi G, et al. Obsessive-compulsive disorder, insulin signaling and diabetes– a novel form of physical health comorbidity: the sweet compulsive brain. Compr Psychiatr. 2022;117:152329.CrossRef Grassi G, et al. Obsessive-compulsive disorder, insulin signaling and diabetes– a novel form of physical health comorbidity: the sweet compulsive brain. Compr Psychiatr. 2022;117:152329.CrossRef
50.
go back to reference Kontoangelos K, et al. The association of the metabolic profile in diabetes mellitus type 2 patients with obsessive-compulsive symptomatology and depressive symptomatology: new insights. Int J Psychiatry Clin Pract. 2013;17(1):48–55.PubMedCrossRef Kontoangelos K, et al. The association of the metabolic profile in diabetes mellitus type 2 patients with obsessive-compulsive symptomatology and depressive symptomatology: new insights. Int J Psychiatry Clin Pract. 2013;17(1):48–55.PubMedCrossRef
51.
go back to reference Wittchen H-U, Mühlig S, Beesdo K. Mental disorders in primary care. Dialog Clin Neurosci. 2003;5(2):115–28.CrossRef Wittchen H-U, Mühlig S, Beesdo K. Mental disorders in primary care. Dialog Clin Neurosci. 2003;5(2):115–28.CrossRef
52.
go back to reference Calkin CV, Cairns CK. K, et al., Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD study): a randomized, Quadruple-Masked, placebo-controlled clinical trial. The Journal of Clinical Psychiatry; 2022. Calkin CV, Cairns CK. K, et al., Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD study): a randomized, Quadruple-Masked, placebo-controlled clinical trial. The Journal of Clinical Psychiatry; 2022.
53.
go back to reference de Silva VA, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.PubMedPubMedCentralCrossRef de Silva VA, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.PubMedPubMedCentralCrossRef
54.
go back to reference Hakami AY, Ahmad FR, Al-Samadani RG, Salamatullah AH, Baljoon HK, Alghamdi JM, Ramadani Sindi LJ MH and, Ahmed ME. The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study. Psychiatry, 2022. Hakami AY, Ahmad FR, Al-Samadani RG, Salamatullah AH, Baljoon HK, Alghamdi JM, Ramadani Sindi LJ MH and, Ahmed ME. The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study. Psychiatry, 2022.
55.
go back to reference Fitzgerald I, et al. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 2022;25(1):15–22.PubMedCrossRef Fitzgerald I, et al. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 2022;25(1):15–22.PubMedCrossRef
56.
go back to reference Mc Namara KP, et al. Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness? Med J Aust. 2022;217(Suppl 7):S29–33.PubMedPubMedCentral Mc Namara KP, et al. Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness? Med J Aust. 2022;217(Suppl 7):S29–33.PubMedPubMedCentral
Metadata
Title
Mind in Metabolism – A Comprehensive Literature Review on Diabetes and its Connections to Obsessive Compulsive Disorder, Schizophrenia, and Bipolar Disorder
Authors
Anja Cannon
Caitlon Jacoby
Allyson S. Hughes
Publication date
09-12-2024

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more